CEP-14083

CAT: 0804-HY-14243Size: 1 EachDry Ice: NoHazardous: No
CAT#:0804-HY-14243Size:1 Each
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
CEP-14083 is a ATP-competitive ALK kinase inhibitor with an IC50 value in enzymatic assays of 2 nM. CEP-14083 also inhibits other kinases, such as insulin receptor (IR), vascular endothelial growth factor receptor 2 (VEGFR2), angiopoietin-1 receptor (TIE2) and dual leucine zipper kinase (DLK) . CEP-14083 suppresses CD274 mRNA expression and the NPM/ALK function in the NPM/ALK-carrying T cell lymphoma (ALK+TCL) cells. CEP-14083 is promising for research of lymphoma[1][2].
CAS Number
[856692-39-2]
UNSPSC
12352005
Target
Anaplastic lymphoma kinase (ALK) ; Insulin Receptor; Tie; VEGFR
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/cep-14083.html
Smiles
CN1N=C2CCC3=C4N(C5=CC=C(C=C5C4=C(CNC6=O)C6=C3C2=C1)NC(N(C7=CC=CC=C7)C)=O)CCC
Molecular Formula
C31H30N6O2
Molecular Weight
518.61
References & Citations
[1]Puig de la Bellacasa R, et al. ALK and ROS1 as a joint target for the treatment of lung cancer: a review. Transl Lung Cancer Res. 2013 Apr;2 (2) :72-86.|[2]Marzec M, et al. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1) . Proc Natl Acad Sci U S A. 2008 Dec 30;105 (52) :20852-7.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Popular Products